JP6847114B2 - 3’−o−メチル−4’−o−サルフェートエピカテキンを含む組成物及びかかる組成物の治療的使用 - Google Patents
3’−o−メチル−4’−o−サルフェートエピカテキンを含む組成物及びかかる組成物の治療的使用 Download PDFInfo
- Publication number
- JP6847114B2 JP6847114B2 JP2018533185A JP2018533185A JP6847114B2 JP 6847114 B2 JP6847114 B2 JP 6847114B2 JP 2018533185 A JP2018533185 A JP 2018533185A JP 2018533185 A JP2018533185 A JP 2018533185A JP 6847114 B2 JP6847114 B2 JP 6847114B2
- Authority
- JP
- Japan
- Prior art keywords
- individual
- composition
- use according
- methyl
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 115
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 title claims description 60
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 title claims description 60
- 235000012734 epicatechin Nutrition 0.000 title claims description 60
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 title claims description 59
- 230000001225 therapeutic effect Effects 0.000 title claims description 11
- 235000013305 food Nutrition 0.000 claims description 43
- 206010020772 Hypertension Diseases 0.000 claims description 32
- 230000001965 increasing effect Effects 0.000 claims description 24
- 230000017531 blood circulation Effects 0.000 claims description 22
- 230000035935 pregnancy Effects 0.000 claims description 22
- 201000011461 pre-eclampsia Diseases 0.000 claims description 19
- 230000004580 weight loss Effects 0.000 claims description 19
- 208000030941 fetal growth restriction Diseases 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 208000004104 gestational diabetes Diseases 0.000 claims description 16
- 208000001362 Fetal Growth Retardation Diseases 0.000 claims description 15
- 206010070531 Foetal growth restriction Diseases 0.000 claims description 15
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 13
- 208000010877 cognitive disease Diseases 0.000 claims description 12
- 235000015872 dietary supplement Nutrition 0.000 claims description 12
- 230000036651 mood Effects 0.000 claims description 12
- 235000016709 nutrition Nutrition 0.000 claims description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 11
- 206010022489 Insulin Resistance Diseases 0.000 claims description 11
- 235000005911 diet Nutrition 0.000 claims description 11
- 239000008103 glucose Substances 0.000 claims description 11
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 10
- 238000012384 transportation and delivery Methods 0.000 claims description 9
- 206010048554 Endothelial dysfunction Diseases 0.000 claims description 8
- 206010033307 Overweight Diseases 0.000 claims description 8
- 230000036772 blood pressure Effects 0.000 claims description 8
- 230000037213 diet Effects 0.000 claims description 8
- 230000008694 endothelial dysfunction Effects 0.000 claims description 8
- 208000000044 Amnesia Diseases 0.000 claims description 7
- 210000004204 blood vessel Anatomy 0.000 claims description 7
- 230000001149 cognitive effect Effects 0.000 claims description 7
- 239000003102 growth factor Substances 0.000 claims description 7
- 238000012423 maintenance Methods 0.000 claims description 7
- 238000001243 protein synthesis Methods 0.000 claims description 7
- 230000014616 translation Effects 0.000 claims description 7
- 208000008589 Obesity Diseases 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 230000036737 immune function Effects 0.000 claims description 6
- 235000020824 obesity Nutrition 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 238000012549 training Methods 0.000 claims description 6
- 208000031091 Amnestic disease Diseases 0.000 claims description 5
- 206010012289 Dementia Diseases 0.000 claims description 5
- 208000019022 Mood disease Diseases 0.000 claims description 5
- 230000032683 aging Effects 0.000 claims description 5
- 230000006986 amnesia Effects 0.000 claims description 5
- 230000006999 cognitive decline Effects 0.000 claims description 5
- 230000002708 enhancing effect Effects 0.000 claims description 5
- 230000008774 maternal effect Effects 0.000 claims description 5
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 5
- 230000004936 stimulating effect Effects 0.000 claims description 5
- 206010035138 Placental insufficiency Diseases 0.000 claims description 4
- 210000004556 brain Anatomy 0.000 claims description 4
- 230000010339 dilation Effects 0.000 claims description 4
- 238000005265 energy consumption Methods 0.000 claims description 4
- 230000006651 lactation Effects 0.000 claims description 4
- 235000020845 low-calorie diet Nutrition 0.000 claims description 4
- 230000003647 oxidation Effects 0.000 claims description 4
- 238000007254 oxidation reaction Methods 0.000 claims description 4
- 210000002820 sympathetic nervous system Anatomy 0.000 claims description 4
- 235000015263 low fat diet Nutrition 0.000 claims description 3
- 208000002296 eclampsia Diseases 0.000 claims description 2
- 235000020855 low-carbohydrate diet Nutrition 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 229910021653 sulphate ion Inorganic materials 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000034920 Body Weight Maintenance Diseases 0.000 claims 1
- 230000003931 cognitive performance Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000005995 skin dysfunction Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 41
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 16
- 201000010099 disease Diseases 0.000 description 15
- 241000282412 Homo Species 0.000 description 12
- 230000015654 memory Effects 0.000 description 11
- -1 Epicatechin Glucuronides Chemical class 0.000 description 10
- 230000008901 benefit Effects 0.000 description 9
- 230000019771 cognition Effects 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 239000003925 fat Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 208000002705 Glucose Intolerance Diseases 0.000 description 5
- 208000006011 Stroke Diseases 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000003930 cognitive ability Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 208000029078 coronary artery disease Diseases 0.000 description 5
- 230000035487 diastolic blood pressure Effects 0.000 description 5
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000001605 fetal effect Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 201000009104 prediabetes syndrome Diseases 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000035488 systolic blood pressure Effects 0.000 description 4
- 230000037221 weight management Effects 0.000 description 4
- 206010019280 Heart failures Diseases 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 230000003292 diminished effect Effects 0.000 description 3
- 230000002996 emotional effect Effects 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 150000002116 epicatechin Chemical class 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000001631 hypertensive effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- 208000007530 Essential hypertension Diseases 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 101000764872 Homo sapiens Transient receptor potential cation channel subfamily A member 1 Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 201000004239 Secondary hypertension Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 2
- 235000005487 catechin Nutrition 0.000 description 2
- 230000035606 childbirth Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- RTIXKCRFFJGDFG-UHFFFAOYSA-N chrysin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 RTIXKCRFFJGDFG-UHFFFAOYSA-N 0.000 description 2
- 229950001002 cianidanol Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 229930003949 flavanone Natural products 0.000 description 2
- 150000002208 flavanones Chemical class 0.000 description 2
- 235000011981 flavanones Nutrition 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002213 flavones Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000005802 health problem Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- NYCXYKOXLNBYID-UHFFFAOYSA-N 5,7-Dihydroxychromone Natural products O1C=CC(=O)C=2C1=CC(O)=CC=2O NYCXYKOXLNBYID-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010004954 Birth trauma Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- QAGGICSUEVNSGH-UHFFFAOYSA-N Diosmetin Natural products C1=C(O)C(OC)=CC=C1C1=CC(=O)C2=CC=C(O)C=C2O1 QAGGICSUEVNSGH-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- GQODBWLKUWYOFX-UHFFFAOYSA-N Isorhamnetin Natural products C1=C(O)C(C)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 GQODBWLKUWYOFX-UHFFFAOYSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 206010038926 Retinopathy hypertensive Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010040613 Shoulder Dystocia Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000003566 TRPV1 Human genes 0.000 description 1
- 102100026186 Transient receptor potential cation channel subfamily A member 1 Human genes 0.000 description 1
- 101150016206 Trpv1 gene Proteins 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003935 attention Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 230000037237 body shape Effects 0.000 description 1
- 235000015496 breakfast cereal Nutrition 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 235000012182 cereal bars Nutrition 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000015838 chrysin Nutrition 0.000 description 1
- 229940043370 chrysin Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 235000015428 diosmetin Nutrition 0.000 description 1
- MBNGWHIJMBWFHU-UHFFFAOYSA-N diosmetin Chemical compound C1=C(O)C(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 MBNGWHIJMBWFHU-UHFFFAOYSA-N 0.000 description 1
- 229960001876 diosmetin Drugs 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000027700 hepatic dysfunction Diseases 0.000 description 1
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 description 1
- 229960001587 hesperetin Drugs 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 201000009939 hypertensive encephalopathy Diseases 0.000 description 1
- 201000001948 hypertensive retinopathy Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000009593 intrauterine fetal growth Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- IZQSVPBOUDKVDZ-UHFFFAOYSA-N isorhamnetin Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 IZQSVPBOUDKVDZ-UHFFFAOYSA-N 0.000 description 1
- 235000008800 isorhamnetin Nutrition 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000008449 language Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000018773 low birth weight Diseases 0.000 description 1
- 231100000533 low birth weight Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000003924 mental process Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 235000020166 milkshake Nutrition 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000004796 pathophysiological change Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 238000013439 planning Methods 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000019685 rice crackers Nutrition 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000011257 shell material Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 235000013570 smoothie Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000005496 tempering Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000036266 weeks of gestation Effects 0.000 description 1
- 235000008924 yoghurt drink Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pediatric Medicine (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Botany (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
Description
[0029]
[0062]
A. 3’−O−メチル−4’−O−サルフェートエピカテキンを含む組成物を個体に投与することを含む、血管の拡張及び/又は体内の組織への血流送達の増加のための方法。
B. かかる個体が、高血圧又は心臓血管疾患を有する又はその危険性がある、段落Aに記載の方法。
C. かかる組成物が、血圧の低下、血液循環の改善、脳の血液循環の改善、内皮機能不全の軽減、タンパク質合成の刺激、増殖因子の放出増加、免疫機能の増強、及びそれらの組み合わせからなる群から選択される治療効果を達成する量で個体に投与される、段落A又はBに記載の方法。
D. かかる組成物が、インスリン抵抗性、耐糖能及びこれらの組み合わせからなる群から選択される特性を改善する量で前記個体に投与される、段落Aに記載の方法。
E. かかる個体が、早産児、子宮内胎児発育遅延を経験した乳児、妊娠性糖尿病に罹患している妊婦、妊娠高血圧症、子癇前症、子癇、及び/又は胎盤機能不全、インスリン抵抗性を有するヒト、耐糖能障害に罹患しているヒト、及びII型糖尿病に罹患しているヒトからなる群から選択される、段落Dに記載の方法。
F. かかる組成物が、認知能力、認知、気分、又は記憶のうち1つ以上を改善する量で個体に投与される、段落Aに記載の方法。
G. かかる個体が、認知機能の低下、軽度認知障害、認知症、気分障害、記憶喪失、及びこれらの組み合わせからなる群から選択される状態を有する、段落Fに記載の方法。
H. かかる個体が、認知加齢を有する高齢者である、段落F又はGに記載の方法。
I. 3’−O−メチル−4’−O−サルフェートエピカテキンを含む組成物を個体に投与することを含む、体重維持又は体重減量のための方法。
J. かかる組成物が、体重維持又は体重減量を促進するのに有効な量で追加成分を更に含む、段落Iに記載の方法。
K. かかる組成物が、エネルギー消費、交感神経系活性、及び脂肪の酸化からなる群から選択される少なくとも1つの特性を増加させる量の3’−O−メチル−4’−O−サルフェートエピカテキンを提供するよう投与される、段落I又はJに記載の方法。
L. かかる個体が肥満症又は過体重を有する、又はこれらの危険性がある、段落I〜Kのいずれか一段落に記載の方法。
M. 3’−O−メチル−4’−O−サルフェートエピカテキンを含む組成物を、内皮機能不全の治療若しくは予防を必要としている又はこれらの危険性のある個体に投与することを含む、内皮機能不全を治療又は予防するための方法。
N. 3’−O−メチル−4’−O−サルフェートエピカテキンを含む組成物を、子癇前症及び/又はIUGRの治療若しくは予防を必要としている又はこれらの危険性のある個体に投与することを含む、子癇前症及び/又はIUGRを治療又は予防するための方法。
O. 3’−O−メチル−4’−O−サルフェートエピカテキンを含む組成物を、妊娠性糖尿病の治療若しくは予防を必要としている又はこれらの危険性のある個体に投与することを含む、妊娠性糖尿病を治療又は予防するための方法。
P. 妊娠しようとしている個体のその妊娠前に、及び/又は、個体の妊娠中に、及び/又は、授乳中に、個体にかかる組成物を投与する、段落N又はOに記載の方法。
Q. かかる組成物がかかる個体に注入される、段落A〜Pのいずれか一段落に記載の方法。
R. 本組成物が、食品製品の少なくとも0.01mg/gの濃度で3’−O−メチル−4’−O−サルフェートエピカテキンが存在する食品製品として個体に経口投与される、段落A〜Pのいずれか一段落に記載の方法。
S. 本組成物が、前記組成物の少なくとも0.01mg/gの濃度で3’−O−メチル−4’−O−サルフェートエピカテキンが存在する母体用栄養補助剤として個体に経口投与される、段落N〜Pのいずれか一段落に記載の方法。
Claims (33)
- 個体における血管の拡張及び/又は体内の組織への血流送達の増加のための組成物を製造するための3’−O−メチル−4’−O−サルフェートエピカテキンの使用。
- 前記組成物が、食品製品の少なくとも0.01mg/gの濃度で前記3’−O−メチル−4’−O−サルフェートエピカテキンが存在する前記食品製品として前記個体に経口投与されるものである、請求項1に記載の使用。
- 前記組成物が、少なくとも1週間にわたって、少なくとも1日1回、前記個体に投与されるものである、請求項1に記載の使用。
- 前記3’−O−メチル−4’−O−サルフェートエピカテキンが化学的に合成されるものである、請求項1に記載の使用。
- 前記個体が高血圧を有する、又は高血圧の危険性がある、請求項1に記載の使用。
- 前記個体が心臓血管疾患を有する、又は心臓血管疾患の危険性がある、請求項1に記載の使用。
- 前記組成物が、血圧の低下、血液循環の改善、脳の血液循環の改善、内皮機能不全の軽減、タンパク質合成の刺激、増殖因子の放出増加、免疫機能の増強、及びこれらの組み合わせからなる群から選択される治療効果を達成する量で前記個体に投与されものである、請求項1に記載の使用。
- 前記組成物が、インスリン抵抗性、耐糖能及びこれらの組み合わせからなる群から選択される特性を改善する量で前記個体に投与されるものである、請求項1に記載の使用。
- 前記個体が、早産児、子宮内胎児発育遅延を経験した乳児、妊娠性糖尿病に罹患している妊婦、妊娠高血圧症、子癇前症、子癇、及び/又は胎盤機能不全、インスリン抵抗性を有するヒト、耐糖能障害に罹患しているヒト、及びII型糖尿病に罹患しているヒトからなる群から選択される、請求項8に記載の使用。
- 前記組成物が、認知能力、認知、気分又は記憶の1つ以上を改善する量で前記個体に投与されるものである、請求項1に記載の使用。
- 前記個体が、認知機能の低下、軽度認知障害、認知症、気分障害、記憶喪失及びこれらの組み合わせからなる群から選択される状態を有する、請求項10に記載の使用。
- 前記個体が認知加齢を有する高齢者である、請求項10に記載の使用。
- 前記組成物が、前記個体に注入されるものである、請求項1に記載の使用。
- 個体の体重維持又は体重減量のための組成物を製造するための3’−O−メチル−4’−O−サルフェートエピカテキンの使用。
- 前記組成物が、食品製品の少なくとも0.01mg/gの濃度で前記3’−O−メチル−4’−O−サルフェートエピカテキンが存在する前記食品製品として前記個体に経口投与されるものである、請求項14に記載の使用。
- 前記組成物が、少なくとも1週間にわたって、少なくとも1日1回、前記個体に投与されるものである、請求項14に記載の使用。
- 前記3’−O−メチル−4’−O−サルフェートエピカテキンが化学的に合成されるものである、請求項14に記載の使用。
- 前記組成物が体重維持又は体重減量を促進するのに有効な量で追加成分を更に含む、請求項14に記載の使用。
- 前記組成物が、エネルギー消費、交感神経系活性、及び脂肪の酸化からなる群から選択される少なくとも1つの特性を増加させる量の3’−O−メチル−4’−O−サルフェートエピカテキンを提供するよう投与されるものである、請求項14に記載の使用。
- 前記個体が肥満症又は過体重を有する、又はこれらの危険性がある、請求項14に記載の使用。
- 前記個体が低脂肪食、低炭水化物食、低カロリー食、超低カロリー食、耐久トレーニング、筋力トレーニング及びこれらの組み合わせからなる群から選択される体重減量プログラムに参加している、請求項14に記載の使用。
- 前記組成物が、前記個体に注入されるものである、請求項14に記載の使用。
- 内皮機能不全の治療若しくは予防を必要としている又はこれらの危険性のある個体を対象とした内皮機能不全を治療又は予防するための組成物を製造するための3’−O−メチル−4’−O−サルフェートエピカテキンの使用。
- 前記組成物が、食品製品の少なくとも0.01mg/gの濃度で前記3’−O−メチル−4’−O−サルフェートエピカテキンが存在する前記食品製品として前記個体に経口投与されるものである、請求項23に記載の使用。
- 前記組成物が、少なくとも1週間にわたって、少なくとも1日1回、前記個体に投与されるものである、請求項23に記載の使用。
- 子癇前症及び/又はIUGRの治療若しくは予防を必要としている又はこれらの危険性のある個体を対象とした子癇前症及び/又はIUGRを治療又は予防するための組成物を製造するための3’−O−メチル−4’−O−サルフェートエピカテキンの使用。
- 前記組成物が、前記組成物の少なくとも0.01mg/gの濃度で前記3’−O−メチル−4’−O−サルフェートエピカテキンが存在する母体用栄養補助剤として前記個体に経口投与されるものである、請求項26に記載の使用。
- 前記組成物が、妊娠しようとしている前記個体のその妊娠前に、及び/又は、前記個体の妊娠中に、前記個体に投与されるものである、請求項26又は27に記載の使用。
- 妊娠性糖尿病の治療若しくは予防を必要としている又はこれらの危険性のある個体を対象とした妊娠性糖尿病を治療又は予防するための組成物を製造するための3’−O−メチル−4’−O−サルフェートエピカテキンの使用。
- 前記組成物が、前記組成物の少なくとも0.01mg/gの濃度で前記3’−O−メチル−4’−O−サルフェートエピカテキンが存在する母体用栄養補助剤として前記個体に経口投与されるものである、請求項29に記載の使用。
- 前記組成物が、妊娠しようとしている前記個体のその妊娠前に、及び/又は、前記個体の妊娠中に、及び/又は、授乳中に、前記個体に投与されるものである、請求項29又は30に記載の使用。
- 前記組成物が、3’−O−メチル−4’−O−サルフェートエピカテキンを富化した抽出物の形態である、請求項1〜31のいずれか一項に記載の使用。
- 前記組成物が、医療用食品、栄養組成物、医薬品、食品組成物、又はペットフード組成物である、請求項1〜32のいずれか一項に記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662287055P | 2016-01-26 | 2016-01-26 | |
US62/287,055 | 2016-01-26 | ||
PCT/EP2017/050657 WO2017129421A1 (en) | 2016-01-26 | 2017-01-13 | Compositions comprising 3'-o-methyl-4'-o-sulfate epicatechin and therapeutic uses of such compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019504036A JP2019504036A (ja) | 2019-02-14 |
JP6847114B2 true JP6847114B2 (ja) | 2021-03-24 |
Family
ID=57906596
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018533185A Active JP6847114B2 (ja) | 2016-01-26 | 2017-01-13 | 3’−o−メチル−4’−o−サルフェートエピカテキンを含む組成物及びかかる組成物の治療的使用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20210196671A1 (ja) |
EP (1) | EP3407882A1 (ja) |
JP (1) | JP6847114B2 (ja) |
CN (1) | CN108463220A (ja) |
WO (1) | WO2017129421A1 (ja) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6297273B1 (en) * | 1996-04-02 | 2001-10-02 | Mars, Inc. | Use of cocoa solids having high cocoa polyphenol content in tabletting compositions and capsule filling compositions |
GB0719542D0 (en) * | 2007-10-08 | 2007-11-14 | Barry Callebaut Ag | Use of cocoa extract |
EP2557079A1 (en) * | 2011-08-09 | 2013-02-13 | Nestec S.A. | Synthesis of catechin and epicatechin conjugates |
-
2017
- 2017-01-13 EP EP17701647.4A patent/EP3407882A1/en not_active Withdrawn
- 2017-01-13 WO PCT/EP2017/050657 patent/WO2017129421A1/en active Application Filing
- 2017-01-13 JP JP2018533185A patent/JP6847114B2/ja active Active
- 2017-01-13 CN CN201780005361.7A patent/CN108463220A/zh active Pending
- 2017-01-13 US US16/071,241 patent/US20210196671A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP3407882A1 (en) | 2018-12-05 |
JP2019504036A (ja) | 2019-02-14 |
CN108463220A (zh) | 2018-08-28 |
WO2017129421A1 (en) | 2017-08-03 |
US20210196671A1 (en) | 2021-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI722992B (zh) | 腦功能改善劑、及認知功能障礙的預防或治療劑 | |
JP7163460B2 (ja) | 桂皮アルデヒド及び亜鉛を含む組成物並びにかかる組成物の使用方法 | |
JP2019142940A (ja) | 桂皮アルデヒド及び亜鉛を含む組成物並びにかかる組成物の使用方法 | |
WO2017176199A1 (en) | A macronutrient composition for use in a method for treatment of gestational diabetes | |
JP6847114B2 (ja) | 3’−o−メチル−4’−o−サルフェートエピカテキンを含む組成物及びかかる組成物の治療的使用 | |
US20090181974A1 (en) | Composition for slowing down the development of alzheimer's disease | |
US20210196672A1 (en) | Compositions comprising 3'-o-methyl-5-o-sulfate epicatechin and therapeutic uses of such compositions | |
US20200261485A1 (en) | Compositions comprising 3'-o-glucuronide epicatechin and methods of making and using such compositions | |
US20190000868A1 (en) | Compositions comprising 4'-o-glucuronide epicatechin and methods of making and using such compositions | |
Hazra et al. | Ghee as medicine | |
JP2016525134A (ja) | チグリンアルデヒドを使用する組成物及び方法 | |
CN109481446B (zh) | 改善孕妇产妇乳母胎儿机体功能的组合物及制备工艺 | |
Nunes et al. | The importance of studying metabolism in pregnancy | |
CA2985564C (en) | Compositions comprising cinnamaldehyde and zinc and methods of using such compositions | |
Makhmatovich et al. | Diagnosis and treatment of iron deficiency anemia in early pregnancy | |
Tait | 'One day, it could be my child who needs it': Exploring Reasons for Breast Milk Donation in Rio de Janeiro, Brazil |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20190614 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200109 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201027 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210119 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210209 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210302 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6847114 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |